Source: STEP 1 trial data (Wilding et al., NEJM 2021) Tip: If side effects are severe at a new dose, your prescriber may hold the current level for an extra 4 weeks or drop back to the previous dose temporarily
However, when IGFBP-1 levels are chronically lowered during prolonged intra-portal hyperinsulinemia (e.g., obesity, Cushings syndrome and glucocorticoid therapy), the accelerator effect of IGFBP-1 is at play to increase serum free IGF-I (35, 40)
Trajectory analyses included the calculation of Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), and proteinligand contact maps
How It Works Tesamorelin binds to GHRH receptors in the anterior pituitary, increasing pulsatile growth hormone and downstream IGF1, which selectively stimulates lipolysis in visceral adipose tissue while largely preserving subcutaneous fat and lean muscle